9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Capecitabine in Treating Patients With Malignant Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 27 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CALGB-39807|U10CA031946|CLB-39807|CDR0000067422 Study First Received: January 21, 2000 Last Updated: July 12, 2016 Estimated Primary Completion Date: December 2003 Primary Outcome Measures: Sponsors and Collaborators: Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00004183...

Continue reading

Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 59 Age Group: up to 69 Years   (Child, Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Primary Purpose: Treatment Study ID Numbers: EORTC-08031|2004-004273-28 Study First Received: September 26, 2005 Last Updated: July 17, 2012 Estimated Primary Completion Date: August 2007 Primary Outcome Measures: Feasibility in terms of 90-day progression-free survival|Toxicity|Progression-free survival|Overall survival Sponsors and Collaborators: European Organisation for Research and Treatment of Cancer - EORTC Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00227630...

Continue reading

Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 82 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: EORTC-08052|JJPRD-26866138CAN2012|2006-000009-51 Study First Received: April 9, 2007 Last Updated: April 19, 2013 Estimated Primary Completion Date: April 2010 Primary Outcome Measures: Progression-free survival (PFS) rate at 18 weeks|Overall objective response rate|Symptomatic response rate|Safety as measured by NCI CTCAE v3.0 and the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity questionnaire|Duration of PFS|Overall survival Sponsors and Collaborators: European Organisation for Research and Treatment of Cancer - EORTC Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00458913...

Continue reading

Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 12 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000269674|RPCI-RP-9812 Study First Received: February 5, 2003 Last Updated: February 25, 2011 Estimated Primary Completion Date: June 2006 Primary Outcome Measures: Feasibility|Comparison of results from this regimen to historical controls|Toxic effects Sponsors and Collaborators: Roswell Park Cancer Institute Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00054002...

Continue reading

Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 57 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NGR010|EUDRACT Number: 2006-005993-39 Study First Received: June 7, 2007 Last Updated: October 26, 2015 Estimated Primary Completion Date: September 2010 Primary Outcome Measures: • Antitumor activity defined as progression free survival (PFS)|• Tumor Growth Control Rate (TGCR) according to RECIST criteria • Overall survival (OS)|• Experimental Imaging Study (DCE-MRI)|• Pharmacokinetics in patients treated with weekly schedule|•Safety Sponsors and Collaborators: MolMed S.p.A. Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00484276...

Continue reading

S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery

Condition Malignant Mesothelioma Estimated Enrollment: 57 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000066832|SWOG-S9810|U10CA032102 Study First Received: November 1, 1999 Last Updated: October 5, 2012 Estimated Primary Completion Date: June 2007 Primary Outcome Measures: Estimate overall survival|qualitative and quantitative toxicities|confirmed and unconfirmed complete and partial response Sponsors and Collaborators: Southwest Oncology Group|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00003723...

Continue reading

PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 47 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CALGB-30107|U10CA031946|CDR0000269537 Study First Received: February 5, 2003 Last Updated: June 30, 2016 Estimated Primary Completion Date: July 2005 Primary Outcome Measures: Survival|Failure free survival Sponsors and Collaborators: Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00053885...

Continue reading

Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung

Condition Malignant Mesothelioma Estimated Enrollment: 61 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: SAKK 17/00|SWS-SAKK-17-00|EU-20136 Study First Received: February 14, 2002 Last Updated: May 14, 2012 Estimated Primary Completion Date: May 2003 Primary Outcome Measures: Sponsors and Collaborators: Swiss Group for Clinical Cancer Research Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00030745...

Continue reading

SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma

Condition Mesothelioma Estimated Enrollment: 24 Age Group: 18 Years to 100 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment Study ID Numbers: 080026|08-C-0026 Study First Received: September 30, 2011 Last Updated: April 20, 2017 Estimated Primary Completion Date: January 31, 2014 Primary Outcome Measures: Safety and MTD|Best overall response Sponsors and Collaborators: National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01445392...

Continue reading

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Condition Pleural Malignant Mesothelioma Estimated Enrollment: 14 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Primary Purpose: Treatment Study ID Numbers: UPCC 03510 Study First Received: April 27, 2010 Last Updated: December 14, 2015 Estimated Primary Completion Date: October 2012 Primary Outcome Measures: 3-month PFS rate|Estimate the distribution of progression-free and over survival Sponsors and Collaborators: Abramson Cancer Center of the University of Pennsylvania Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01112293...

Continue reading